Miss Claire Gaunt

Institute of Cancer and Genomic Sciences
Trial Management Team Manager

Contact details

Cancer Research UK Clinical Trials Unit (CRCTU)
Institute of Cancer and Genomic Sciences
University of Birmingham
B15 2TT


BSc Honours in Applied Sciences (Biomedical Science & Human Biology) 2.2 University of Wolverhampton, UK


Claire Gaunt graduated with a BSc. (Hons) in Biomedical Science and Human Biology from the University of Wolverhampton in 1997. She then worked for Southern Birmingham Health authority before joining the Cancer Research Clinical Trials Unit (CRCTU) as a Data Manager in 2000. 

Since then, Claire has held various trial management posts within the CRCTU, gaining experience in the fields of supportive care and breast cancer clinical trials before being appointed as a Senior Trial Coordinator within the B Team in 2010. As a Senior Trial Coordinator, Claire managed the supportive care portfolio and helped to secure government funding to coordinate the LORIS trial, a surgical study, which aims to address overtreatment in non-invasive breast disease.

In May 2014, Claire was appointed as Adult Late Phase Team Leader (Team B) within CRCTU, working closely with local specialist leads in the areas of breast, skin, head and neck cancer and supportive care and supporting external investigators.


Clinical Trials. Breast Cancer. Head and Neck Cancer. Skin Cancer. Supportive Care. Haematological Cancer.


SMALL: Paper; Editorial. Morgan, J., Potter, S., Sharma, N., McIntosh, S. A., Coles, C. E., Dodwell, D., Elder, K., Gaunt, C., Lyburn, I. D., McIntosh, S. A., Morgan, J., Paramasivan, S., Pinder, S., Pirrie, S., Potter, S., Rea, D., Roberts, T., Sharma, N., Stobart, H., Taylor-Phillips, S., Wallis, M., Wilcox, M. The SMALL trial: A big change for small breast cancers. Clinical Oncology. 2019;31(9):659-63.

Cameron, D., Morden, J. P., Canney, P., Velikova, G., Coleman, R., Bartlett, J., Gaunt, C. et al. (2017). Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer in the randomised UK TACT2 trial (CRUK/05/19): A multicentre, phase 3, open-label, randomised, controlled trial. The Lancet.Oncology.

Coleman, R. E., Marshall, H., Cameron, D., DodwellL, D., Burkishaw, R., KeaneE, M., Gil, M., Houston, S. J., Grieve, R. J., Barrett-Lee, P. J., Ritchie, D., Pugh, J., Gaunt, C., Rea R., Peterson, J., Davies, C., Hiley, V., Gregory, W. & Bell, R. 2011. Breast-cancer adjuvant therapy with zoledronic acid. N Engl J Med, 365, 1396-405

Cullen MH, Billingham LJ, Gaunt CH, Steven NM. Rational selection of patients for antibacterial prophylaxis after chemotherapy. J Clin Oncol 2007 Oct 20;25(30):4821-8.

Innes H, Billingham L, Gaunt C, Steven N, Marshall E. Management of febrile neutropenia in the United Kingdom: time for a national trial? Br J Cancer 2005 Dec 12;93(12):1324-8.

Cullen M, Steven N, Billingham L, Gaunt C, Hastings M, Simmonds P, et al. Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomas. N Engl J Med 2005 Sep 8;353(10):988-98.

Cullen MH, Billingham LJ, Gaunt CH, Steven NM. Rational selection of patients for antibacterial prophylaxis after chemotherapy. J Clin Oncol 2007 Oct 20;25(30):4821-8.